Serum Levels of Secreted Group IIA Phospholipase A2 in Benign Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation or Neoplasia?
Serum Levels of Secreted Group IIA Phospholipase A2 in Benign Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation or Neoplasia?
复制标题
DOI：
10.1007/s10753-011-9418-1
复制
发表时间：
2012-06-01
期刊：
影响因子：
5.1
通讯作者：
Siegert, Gabriele
中科院分区：
文献类型：
--
作者：
Menschikowski, Mario;Hagelgans, Albert;Siegert, Gabriele
分泌型IIA族磷脂酶A（2）（sPLA（2）-IIA）在人前列腺癌（PCa）标本和一些PCa衍生细胞系中显著上调，表明该酶在肿瘤发生中的重要作用。在这项研究中，我们检测了sPLA（2）-IIA、C-反应蛋白（CRP）和前列腺特异性抗原（PSA）的水平，这些血清样本来自良性前列腺增生（BPH）和不同阶段的PCa患者。我们发现BPH和PCa患者血清sPLA（2）-IIA和CRP水平与健康人相比显著升高，但这些炎症生物标志物的浓度在BPH和PCa患者之间没有差异。此外，血清sPLA（2）-IIA水平与CRP浓度相关，但与PSA、Gleason分级或肿瘤分期无关。总之，这些研究结果表明，癌症相关的变化不是导致血清sPLA（2）-IIA水平升高的唯一因素，并强调了sPLA（2）-IIA作为BPH和PCa患者炎症循环标志物的实用性。
Secreted group IIA phospholipase A(2) (sPLA(2)-IIA) is markedly up-regulated in human prostate cancer (PCa) specimens and in some PCa-derived cell lines, indicating an important role of this enzyme in tumourigenesis. In this study, we measured levels of sPLA(2)-IIA, C-reactive protein (CRP), and prostate-specific antigen (PSA) in serum samples obtained from patients with benign prostatic hyperplasia (BPH) and with PCa of different stages. We found that serum levels of sPLA(2)-IIA and CRP in BPH and PCa patients were significantly elevated compared to those of healthy individuals, but the concentrations of these inflammatory biomarkers did not differ between patients with BPH or PCa. Furthermore, serum levels of sPLA(2)-IIA correlated with concentrations of CRP, but not with PSA, Gleason grade or tumour stage. In conclusion, these findings suggest that cancer-related changes are not exclusive factors contributing to elevated serum sPLA(2)-IIA levels and emphasize the utility of sPLA(2)-IIA as a circulating marker of inflammation in patients with BPH and PCa.